breast cancer

latest news on cancer research

Research paves way for better drugs for breast cancer

New Delhi, Aug 23: In a study that could help design better drugs for breast cancer, researchers at the Indian Institute of Science Education and Research (IISER)-Bhopal have identified the mechanism by which breast cancer cells proliferate and spread.  The team studied the regulation of a gene called ‘ESRP1’ in breast cancer. They found that there is a difference in the expression of the ESRP1 gene between normal and tumour tissues of breast cancer patients. The gene was expressed more in breast tumour tissues than normal tissues. They then explored the regulatory mechanism behind this. The expression of a gene goes through many steps, the first of which is transcription. The ‘message’ encoded in the DNA of the gene is transcribed into RNA signals by proteins called transcription factors. The team found that in tumour tissues, a transcription factor called E2F1 that regulates transcription of ESRP1 gets up-regulated, thereby increasing its expression and eventually leading to excessive growth of breast cancer cells. The team also found the mechanistic aspects of cancer spread to other parts of the body or what is technically called metastasis. Cancerous tumors create regions of reduced oxygen due to poor blood circulation. It has been known that such oxygen-deprived regions instigate metastasis. The IISER researchers have unraveled the mechanism behind this also. They have shown that the transcription factor E2F1 fails to bind the ESRP1 promoter in oxygen-deprived breast cancer cells, thereby downregulating the expression of ESRP1.  This downregulation may cause the cancerous cells to break free from primary cancer and join the bloodstream to be carried to other parts of the body, thereby resulting in metastasis. The study was led by Dr. Sanjeev Shukla, Associate Professor, and DBT/Wellcome Trust India Alliance Fellow in the Department of Biological Sciences at IISER-Bhopal. The work was supported by the DBT/Wellcome Trust India Alliance Fellowship Grant. Speaking to India Science Wire, Dr. Shukla said, “Our research, for the first time, shows the reason behind an elevated expression of a key gene, ESRP1, in breast tumor tissue supporting tumor progression. Another important part of the discovery was a novel epigenetic…

latest news on cancer research

#Healh: Breast cancer treatment takes a big leap forward

Cancer news India | Cancer care in India | Health news New Delhi, Sep 01 (India Science Wire): Breast-cancer is the most common cancer in women in India. An estimated one in twenty-eight women is likely to develop breast cancer during her lifetime. In urban areas, one in twenty-two women is likely to develop breast cancer during her lifetime as compared to rural areas where one in sixty women develops breast cancer in her lifetime. Earlier research had demonstrated that breast cancer patients had reduced production of a protein in the body called Estrogen-related receptor beta (ERRβ), that resulted in proliferation or rapid division of breast cancer cells and their migration to other parts of the body, and that if the protein can be overexpressed in breast cancer patients, it can result in an improved prognosis and prolonged relapse-free survival. However, it was so far not known as to how and why the production of ERRβ protein was reduced in breast cancer patients. A new study by the cancer research group at the Department of Biotechnology’s Institute of Life Sciences (DBT-ILS) has resolved the mystery and promises to pave the way for developing better drugs for breast cancer. The researchers have unravelled the molecular mechanism for the phenomenon. It is found that the ERRβ protein is a key substrate of the SCF complex and deregulated activation of the SCF complex due to the NEDDylation of Cullin subunits of the SCF complex, targets ERRβ for degradation in breast cancer. Consequently, the team led by Dr. Sandip K Mishra has demonstrated that a molecule called MLN4924 can restore the expression of the ERRβ protein and help reduce cell proliferation and migration of breast cancer cells. The study has also demonstrated that restoration of ERRβ expression in breast cancer with the help of MLN4924, promotes the production of two important tumour suppressors p21 and E-cadherin, involved in the arrest of cell proliferation and migration. Breast cancer is the predominant cause of cancer deaths in underdeveloped countries, representing 14.3% of all cancer deaths. In 2018, 1,62,468 new cases and 87,090 deaths were reported for…

latest news on cancer research

In India, around 5.8 lakh new cases of cancers were diagnosed in women in 2018

In 2020, American Oncology Institute will create 2020 Nyla Volunteers across 13 states in India American Oncology Institute announces the launch of its exclusive Campaign for ‘Cancers in Women’- NYLA, a movement for early detection and prevention of Cancers in Women  Hyderabad, February 09, 2020: American Oncology Institute (AOI), South Asia’s leading chain of cancer hospitals, has unveiled an exclusive campaign called Nyla, a movement for early detection and prevention of Cancers in Women, on the occasion of World Cancer Day across 8 states in India. Chief Guest Dr Namrata Singh, a physiotherapist and avid biker, who is undertaking an all India Bike ride to sensitise women about cancers; Dr Babaiah, Medical Director, American Oncology Institute (AOI); Dr Vijay Vemuri, Regional Director – South & COO; Dr Sudha Sinha, Sr. Medical Oncologist, AOI and Dr M Ravikiran, Facility Director – Operations, American Oncology Institute; formally launched NYLA, on last Tuesday at American Oncology Institute, Hyderabad. In India, around 5.8 lakh new cases of cancers were diagnosed in women in 2018. Breast cancer accounts for 25-32% of all female cancers. Cervical cancer is the second most common cancer and accounted for 16.5% of newly diagnosed cancer cases in women in the year 2018. Ovarian Cancer is the third leading cancer and accounted for about 6.2% of all cancers among women in our country. Breast (27.7%) Cervix Uteri (16.5%) Ovary (6.2%) and Colorectum (3.4%) cancers together account for more than half of all cancers in women. Many of these cancers can be detected early and are highly curable in the early stages. Therefore, it is important to step up and educate our community about cancers in women. Negligence and ignorance are causing a growing number of women to lose the battle to cancer.  Early detection can help more women win the battle against cancer. American Oncology Institute (AOI) announced the launch of NYLA – a movement for early detection and prevention of cancers in women namely Breast Cancer, Cervical Cancer, Ovarian Cancer, Uterine Cancer and Colorectal Cancer. The word ‘NYLA’ is of Arabic origin and means a ‘winner’. Dr Namrata Singh, a…